Stock Events

NeuroBo Pharmaceuticals 

$4.14
25
+$0.04+1.1% Today

Statistics

Day High
-
Day Low
-
52W High
6.75
52W Low
2.9
Volume
14,053
Avg. Volume
50,970
Mkt Cap
34.04M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

9MayConfirmed
Q1 2022
Q2 2022
Q3 2022
Q1 2023
Q2 2023
Q3 2023
Q1 2024
-5.1
-3.41
-1.71
-0.02
Expected EPS
-1.1
Actual EPS
-1.32

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NRBO. It's not an investment recommendation.
Alphabet
68918
GOOGL
Apple
60554
AAPL
Microsoft
56693
MSFT
Amazon
51850
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap32.96B
Biogen focuses on neurodegenerative diseases, directly competing in NeuroBo's therapeutic areas.
Sage Therapeutics
SAGE
Mkt Cap739.64M
Sage Therapeutics specializes in brain health, including treatments for depression and neurological disorders, overlapping with NeuroBo's focus.
Alkermes
ALKS
Mkt Cap4.2B
Alkermes works on central nervous system (CNS) diseases, competing in the same therapeutic area as NeuroBo.
Acadia Pharmaceuticals
ACAD
Mkt Cap2.93B
Acadia Pharmaceuticals targets central nervous system disorders, making it a direct competitor in NeuroBo's market.
AMGEN
AMGN
Mkt Cap177.72B
Amgen has a broad portfolio that includes treatments for neurological disorders, competing with NeuroBo's products.
Ionis Pharmaceuticals
IONS
Mkt Cap6.98B
Ionis Pharmaceuticals develops drugs for neurological disorders, directly competing with NeuroBo's research and development focus.
Vertex Pharmaceuticals
VRTX
Mkt Cap126.85B
Vertex Pharmaceuticals, though primarily known for cystic fibrosis treatments, is expanding into other areas including neurological disorders, potentially competing with NeuroBo.
Regeneron Pharmaceuticals
REGN
Mkt Cap114.81B
Regeneron Pharmaceuticals has a diverse portfolio that includes treatments for neurodegenerative diseases, making it a competitor.
Novartis
NVS
Mkt Cap232.42B
Novartis offers a wide range of healthcare solutions including treatments for neurological conditions, competing with NeuroBo.
Pfizer
PFE
Mkt Cap169.83B
Pfizer has a broad portfolio of medicines, including for neurological conditions, making it a competitor in the same therapeutic area as NeuroBo.

Analyst Ratings

10$Average Price Target
The highest estimate is $10.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

About

Health Technology
Pharmaceuticals: Major
Biotechnology
Manufacturing
Pharmaceutical Preparation Manufacturing
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.
Show more...
CEO
Employees
8
Country
US
ISIN
US64132R1077

Listings

XNAS
US
NRBO